Non-Small Cell Lung Cancer Market, By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Large Cell Neuroendocrine Tumors), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Others), By End User (Hospitals, Homecare, Specialty Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI241

Pages :175

Formats :

Excel and PDF

Industry : Pharmaceutical

Key Developments

In January 2023, Novocure, an oncology company, announced positive results from the LUNAR study, which evaluated the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard therapies for stage 4 non-small cell lung cancer (NSCLC) after progression on or following platinum-based therapy.
In December 2022, the U.S. FDA granted approval to Krazati (adagrasib), a targeted therapy for adult patients with KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Krazati (adagrasib) was developed by Mirati, a commercial stage targeted oncology company.
On March 6, 2022, Bristol Myers Squibb, a U.S.-based multinational pharmaceutical company, acquired Turning Point Therapeutics, a clinical-stage precision oncology company known for its internally developed investigational drugs targeting critical gaps in current cancer treatments. This acquisition expanded Bristol Myers Squibb's oncology portfolio with a leading late-stage precision oncology asset.
On August 23, 2021, Pfizer, a U.S.-based multinational pharmaceutical and biotechnology corporation, completed its acquisition of Trillium Therapeutics Inc., a clinical-stage immuno-oncology company specializing in innovative cancer therapies. This acquisition enhanced Pfizer's leadership in oncology by integrating next-generation investigational immuno-therapeutics focused on hematological malignancies.